RSS   Newsletter   Contact   Advertise with us

Astellas completes acquisition of Audentes Therapeutics

Christian Fernsby ▼ | January 16, 2020
Astellas Pharma announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics.
Acquisition   Astellas
That happened through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition for all of the issued and outstanding shares of common stock of Audentes for a price of US$60.00 per share net to the seller in cash and the subsequent merger of Asilomar with and into Audentes.

Topics: Astellas acquisition Audentes Therapeutics

Astellas commenced the Tender Offer on December 16, 2019, New York City time, and the Tender Offer expired at 12:00 midnight, New York City time, at the end of the day on January 14, 2020.

As of the expiration of the Tender Offer, 35,852,857 shares of Audentes common stock were validly tendered and not properly withdrawn, representing approximately 76.7% of the shares of Audentes common stock outstanding, and such shares have been accepted for payment under the terms of the Tender Offer.